Partnership to drive cell and gene therapy growth in Southeast Asia

eXmoor Pharma, a global CDMO with deep expertise in cell and gene therapies (CGTs), has partnered with Siam Bioscience, a leading biopharmaceutical company in ASEAN, to establish a regional hub for CGT development and manufacturing.

The collaboration aims to accelerate access to advanced therapies across Southeast Asia by combining eXmoor’s technical know-how with Siam Bioscience’s regional infrastructure and market insight. The new centre in Bangkok will offer end-to-end services, from process and analytical development to GMP-compliant clinical and commercial manufacturing, supporting both local innovation and international programmes.

Cell and gene therapies represent the next frontier in medicine, offering potentially curative treatments for conditions such as cancer and rare genetic disorders. However, producing these therapies requires precise, reproducible, and traceable processes. The partnership addresses these challenges while creating a platform for international collaboration, bringing global therapies closer to patients in the region.

Angela Osborne, Executive Chair of eXmoor Pharma, said: “This partnership positions Thailand and Southeast Asia at the forefront of CGT innovation. By combining local leadership with global expertise, we can bring life-changing therapies to patients faster and more efficiently.”

Songpon Deechongkit, CEC at Siam Bioscience, added: “Our joint CGT centre will strengthen translational research and practical commercialisation in the region, supporting both established and emerging therapies while adhering to international standards.”

With Southeast Asia emerging as a hub for advanced biotherapeutics, this strategic partnership not only enhances regional capability but also creates significant opportunities for global developers seeking faster, locally compliant routes to market.

More information online